Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 21, 2012; 18(27): 3527-3536
Published online Jul 21, 2012. doi: 10.3748/wjg.v18.i27.3527
Published online Jul 21, 2012. doi: 10.3748/wjg.v18.i27.3527
Table 1 Correlation between polo-like kinase-1 gene expression and clinicopathological parameters in 56 patients with hepatocellular carcinoma
Clinicopathological parameters | n | Relative PLK1 gene expression (mean ± SE) | P value |
Age (yr) | |||
< 65 | 42 | 18.35 ± 2.95 | 0.5701 |
≥ 65 | 14 | 16.15 ± 5.11 | |
Sex | |||
Male | 49 | 17.24 ± 2.74 | 0.4361 |
Female | 7 | 21.72 ± 6.83 | |
Histologic type of tumor | |||
Well differentiated | 2 | 14.00 ± 13.10 | 0.8462 |
Moderately differentiated | 41 | 17.39 ± 2.92 | |
Poorly differentiated | 13 | 19.69 ± 5.87 | |
Liver cirrhosis | |||
Present | 44 | 16.05 ± 2.42 | 0.4971 |
Absent | 12 | 24.22 ± 7.83 | |
Pathological stage | |||
I | 1 | 5.68 | 0.8492 |
II | 5 | 14.11 ± 6.67 | |
III | 32 | 17.68 ± 2.93 | |
IV | 18 | 19.72 ± 5.74 |
- Citation: Mok WC, Wasser S, Tan T, Lim SG. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J Gastroenterol 2012; 18(27): 3527-3536
- URL: https://www.wjgnet.com/1007-9327/full/v18/i27/3527.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i27.3527